1. Search Result
Search Result
Results for "

BCL-2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

367

Inhibitors & Agonists

3

Biochemical Assay Reagents

6

Peptides

76

Natural
Products

11

Isotope-Labeled Compounds

8

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15531
    Venetoclax
    225+ Cited Publications

    ABT-199; GDC-0199; RG7601

    Bcl-2 Family Autophagy Cancer
    Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
    Venetoclax
  • HY-10087
    Navitoclax
    145+ Cited Publications

    ABT-263

    Bcl-2 Family Cancer
    Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax
  • HY-50907
    ABT-737
    65+ Cited Publications

    Bcl-2 Family Apoptosis Autophagy Mitophagy Inflammation/Immunology Cancer
    ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
    ABT-737
  • HY-130604
    DT2216
    2 Publications Verification

    Bcl-2 Family PROTACs Apoptosis Cancer
    DT2216 is a potent and selective BCL-XL (Bcl-2 family member) degrader based on PROTAC technology. DT2216 causes effective degradation of BCL-XL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets. DT2216 is composed of the Bcl-2 family protein inhibitor Navitoclax-piperazine (HY-44432), a linker, and a VHL E3 ubiquitin ligase (Pink: Navitoclax-piperazine; Blue: VHL ligand; Black: linker) .
    DT2216
  • HY-148026

    BGB 11417

    Bcl-2 Family Cancer
    Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .
    Sonrotoclax
  • HY-112416
    AZD4320
    5 Publications Verification

    Bcl-2 Family Cancer
    AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.
    AZD4320
  • HY-50868
    Bafetinib
    10+ Cited Publications

    INNO-406; NS-187

    Bcr-Abl Src Apoptosis Cancer
    Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
    Bafetinib
  • HY-N2897
    Dihydrokaempferol
    5+ Cited Publications

    Apoptosis Bcl-2 Family Inflammation/Immunology
    Dihydrokaempferol is isolated from Bauhinia championii (Benth). Dihydrokaempferol induces apoptosis and inhibits Bcl-2 and Bcl-xL expression. Dihydrokaempferol is a good candidate for new antiarthritic agents .
    Dihydrokaempferol
  • HY-117288
    S55746
    1 Publications Verification

    BCL201

    Bcl-2 Family Cancer
    S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity .
    S55746
  • HY-10969
    Obatoclax Mesylate
    10+ Cited Publications

    GX15-070 Mesylate

    Bcl-2 Family Autophagy Parasite Infection Cancer
    Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2 . Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity .
    Obatoclax Mesylate
  • HY-15531S

    ABT-199-d8; GDC-0199-d8; RG7601-d8

    Bcl-2 Family Autophagy Cancer
    Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
    Venetoclax-d8
  • HY-129179
    Lisaftoclax
    1 Publications Verification

    APG-2575; BCL-2/BCL-xl inhibitor 1

    Bcl-2 Family Cancer
    Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively .
    Lisaftoclax
  • HY-15191
    Sabutoclax
    1 Publications Verification

    BI-97C1

    Bcl-2 Family Cancer
    Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression .
    Sabutoclax
  • HY-15531R

    ABT-199 (Standard); GDC-0199 (Standard); RG7601 (Standard)

    Reference Standards Bcl-2 Family Autophagy Cancer
    Venetoclax (Standard) is the analytical standard of Venetoclax. This product is intended for research and analytical applications. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
    Venetoclax (Standard)
  • HY-125877
    PROTAC Mcl1 degrader-1
    1 Publications Verification

    PROTACs Bcl-2 Family Cancer
    PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC) based on Cereblon ligand, is a potently and selectively Mcl-1 (Bcl-2 family member) inhibitor with an IC50 of 0.78 μM. PROTAC Mcl1 degrader-1 inhibits Bcl-2 with an IC50 of 0.54 μM .
    PROTAC Mcl1 degrader-1
  • HY-12020
    TW-37
    4 Publications Verification

    Bcl-2 Family Cancer
    TW-37 is a potent Bcl-2 inhibitor with Ki values of 260, 290 and 1110 nM for Mcl-1, Bcl-2 and Bcl-xL, respectively.
    TW-37
  • HY-12011
    HA14-1
    2 Publications Verification

    Bcl-2 Family Cancer
    HA14-1 is a Bcl-2/Bcl-XL antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC50 of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.
    HA14-1
  • HY-132307

    Bcl-2 Family Apoptosis Cancer
    Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent .
    Mcl-1 inhibitor 6
  • HY-125876
    PROTAC Bcl2 degrader-1
    1 Publications Verification

    PROTACs Bcl-2 Family Cancer
    PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1 (Blue: CRBN ligand, Black: linker;Pink: Mcl-1/Bcl-2 inhibitor, Nap-1).
    PROTAC Bcl2 degrader-1
  • HY-142209

    Bcl-2 Family Cancer
    ABBV-167 is a phosphate prodrug of the BCL-2 inhibitor venetoclax .
    ABBV-167
  • HY-129700

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-2 (Compound 6) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor .
    MCL-1/BCL-2-IN-2
  • HY-16014

    Bcl-2 Family Cancer
    A-385358 is a selective inhibitor of Bcl-XL with Kis of 0.80 and 67 nM for Bcl-XL and Bcl-2, respectively.
    A-385358
  • HY-138697

    VOB560

    Bcl-2 Family Apoptosis Cancer
    S65487 (VOB560), a potent and selective BCL-2 inhibitor, is a proagent of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities .
    S65487
  • HY-120882

    UBX1967

    Bcl-2 Family Cancer
    BM-1197 (UBX1967) is a potent and selective inhibitor of dual Bcl-2/Bcl-xL, with IC50s of 3.5 nM and 5.2 nM for Bcl-2 and Bcl-xL, respectively. BM-1197 exhibits antitumor effects both in vitro and in vivo .
    BM-1197
  • HY-119931

    Bcl-2 Family Apoptosis NF-κB Parasite Metabolic Disease Cancer
    2-hydroxychalcone, a natural flavonoid, is a potent antioxidant, inhibiting lipid peroxidation. 2-Hydroxychalcone induces apoptosis by Bcl-2 downregulation. 2-Hydroxychalcone inhibits the activation of NF-kB .
    2-Hydroxychalcone
  • HY-109184
    Murizatoclax
    1 Publications Verification

    AMG 397

    Bcl-2 Family Cancer
    Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a Ki of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer .
    Murizatoclax
  • HY-10087R

    ABT-263 (Standard)

    Reference Standards Bcl-2 Family Cancer
    Navitoclax (Standard) is the analytical standard of Navitoclax. This product is intended for research and analytical applications. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax (Standard)
  • HY-129702

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-4 (Compound 7) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor .
    MCL-1/BCL-2-IN-4
  • HY-129681

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor with IC50s of 4.45 and 3.18 μM, respectively .
    MCL-1/BCL-2-IN-1
  • HY-10969A
    Obatoclax
    10+ Cited Publications

    GX15-070

    Bcl-2 Family Autophagy Parasite Infection Cancer
    Obatoclax (GX15-070), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2 . Obatoclax induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax has anti-cancer and broad-spectrum antiparasitic activity .
    Obatoclax
  • HY-101195

    PKC Phospholipase Bcl-2 Family Apoptosis MMP Inflammation/Immunology Cancer
    DL-erythro-Dihydrosphingosine is a sphingosine-based PKC inhibitor. DL-erythro-Dihydrosphingosine directly inhibits the enzymatic activity of PLA2. DL-erythro-Dihydrosphingosine inhibits the activity of Bcl-2 protein involved in apoptosis. DL-erythro-Dihydrosphingosine inhibits the activity of matrix metalloproteinases (MMP). DL-erythro-Dihydrosphingosine is applicable for research on cancer and inflammatory diseases .
    DL-erythro-Dihydrosphingosine
  • HY-169266

    Bcl-2 Family Apoptosis Metabolic Disease
    BRD-K56819078 is a Bcl-2 inhibitor that significantly reduces senescent cell load and senescence-related genes in the kidney mRNA expression. BRD-K56819078 exerts anti-aging effects by inhibiting apoptosis .
    BRD-K56819078
  • HY-118874A

    Apoptosis Bcl-2 Family Cancer
    Oblimersen sodium is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen sodium specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen sodium can be used for cancer research .
    Oblimersen sodium
  • HY-19551

    ApoG2

    Bcl-2 Family Apoptosis Autophagy Fungal ROS Kinase Infection Cancer
    Apogossypolone (ApoG2) is an orally active Bcl-2 family proteins inhibitor with Ki values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-XL, respectively. Apogossypolone shows antitumor activities, induces cell apoptosis and autophagy . Apogossypolone also has antifungal activity .
    Apogossypolone
  • HY-138697A

    VOB560 sulfate

    Bcl-2 Family Apoptosis Cancer
    S65487 (VOB560) sulfate, a potent and selective Bcl-2 inhibitor, is a proagent of S55746. S65487 sulfate is also active on BCL-2 mutations, such as G101V and D103Y. S65487 sulfate has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 sulfate induces apoptosis and has anticaner activities .
    S65487 sulfate
  • HY-135273

    BCL2-IN-1

    Bcl-2 Family Cancer
    A-1211212 (BCL2-IN-1), a chemical probe, is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM .
    A-1211212
  • HY-156620

    LP-108

    Bcl-2 Family Cancer
    Lacutoclax is a Bcl-2 inhibitor with antineoplastic activity .
    Lacutoclax
  • HY-117288A
    S55746 hydrochloride
    1 Publications Verification

    BCL201 hydrochloride

    Bcl-2 Family Cancer
    S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity .
    S55746 hydrochloride
  • HY-133772

    Drug Metabolite Others
    Venetoclax N-oxide is an impurity of Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM .
    Venetoclax N-oxide
  • HY-177102

    ICP-248

    Bcl-2 Family Cancer
    Mesutoclax (ICP-248) (Compound 5) is a selective BCL-2 inhibitor with an IC50 of 1.54 nM. Mesutoclax has weak activity against BCL-XL (IC50: >1000 nM). Mesutoclax can inhibit the activity of RS4;11 cells with an IC50 of 2.75 nM. Mesutoclax can be used in the study of cancer .
    Mesutoclax
  • HY-118874

    Bcl-2 Family Apoptosis Cancer
    Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research .
    Oblimersen
  • HY-10087S
    Navitoclax-d8
    1 Publications Verification

    Bcl-2 Family Cancer
    Navitoclax-d8 is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax-d8
  • HY-129701

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-3 (Compound 2) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor with IC50s of 5.95 and 4.78 μM, respectively .
    MCL-1/BCL-2-IN-3
  • HY-N1218

    Glycosidase Bcl-2 Family Others
    Stellasterol is a natural product. Stellasterol has high affinity towards Bcl-2 protein (Ki: 118.05 nM). Stellasterol is a weak α-glucosidase inhibitor .
    Stellasterol
  • HY-135275

    Bcl-2 Family Cancer
    BCL-XL-IN-4 (compound 10) is a potent and selective BCL-XL inhibitor with Ki values of 0.042, 170 nM for BCL-XL, BCL-2, respectively. BCL-XL-IN-4 shows cytotoxicity .
    BCL-XL-IN-4
  • HY-177306

    Dynamin Cancer
    Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase) with an IC50 of 3 μM. Opitor-0 can induce fragmentation of mitochondria and remodeling of cristae, disrupt the stability of OPA1 oligomers, and significantly enhance the release of cytochrome c and induce apoptosis. Opitor-0 has a synergistic antitumor effect with Bcl-2 inhibitors, such as ABT-737 (HY-50907) and Venetoclax (HY-15531). Opitor-0 can be used for the research of malignant tumors that are resistant to Bcl-2 inhibitors, such as triple-negative breast cancer (TNBC) .
    Opitor-0
  • HY-175342

    LOXO-338

    Bcl-2 Family Cancer
    FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL .
    FCN-338
  • HY-149681

    Bcl-2 Family Beclin1 Neurological Disease Cancer
    Beclin1-Bcl-2 interaction inhibitor 1 is a Beclin1 and Bcl-2 interaction inhibitor with an IC50 value of 4.4 nM. Beclin1-Bcl-2 interaction inhibitor 1 disrupts the binding of the Bcl-2-Beclin 1 BH3 domain. Beclin1-Bcl-2 interaction inhibitor 1 can be used in the research of cancer and neurodegenerative diseases .
    Beclin1-Bcl-2 interaction inhibitor 1
  • HY-149009

    Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells .
    Bcl-2-IN-9
  • HY-143872

    Bcl-2 Family Cancer
    Bcl-2-IN-4 is a potent, orally active and selective Bcl-2 inhibitor with an IC50 of 1.5 nM. Bcl-2-IN-4 displays >200-fold selectivity over Bcl-xL (IC50 of 411 nM). Bcl-2-IN-4 inhibits RS4; 11 cell proliferation with an IC50 of 2.7 nM (WO2021180040A1; compound 2) .
    Bcl-2-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: